-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Olema Pharmaceuticals, Raises Price Target to $48

Benzinga·12/11/2025 17:53:38
Listen to the news
Oppenheimer analyst Matthew Biegler maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Outperform and raises the price target from $45 to $48.